AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28814660
Drug: ERT monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERT monotherapy
Trial: 28814674
Drug: Rilonacept (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilonacept (loading dose 4.4 mg/kg, followed by 2.2 mg/kg once weekly for 12 months, with dose escalation allowed)
Trial: 28815645
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg/day orally on days 1-21 every 4 weeks
Trial: 28817190
Drug: Filanesib (1.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filanesib (1.50 mg/m²) single agent
Trial: 28817190
Drug: Filanesib (1.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filanesib (1.50 mg/m²) plus dexamethasone (40 mg/week)
Trial: 28817727
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment including 2 mg/kg per day of prednisone equivalent
Trial: 28817753
Drug: Durvalumab, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab, 10 mg/kg every 2 weeks for up to 12 months
Trial: 28817753
Drug: Durvalumab, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab, 10 mg/kg every 2 weeks
Trial: 28818050
Drug: Probiotic administration
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic administration with Bifidobacterium animalis subsp. lactis (BB-12®) and Lactobacillus rhamnosus (LGG®) for 6 months
Trial: 28818061
Drug: Longitudinal mean
RxNorm normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longitudinal mean deviation (MD) and visual acuity (VA) from the Ocular Hypertension Treatment Study (OHTS)
Trial: 28818546
Drug: Glecaprevir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir (300 mg) plus Pibrentasvir (120 mg) once daily for 12 weeks
Trial: 28819385
Drug: Kanglaite Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kanglaite Injection (KLTi) plus Gemcitabine
Trial: 28819927
Drug: Delayed-release prednisone
RxNorm normalized name: prednisone Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release prednisone (DR-prednisone)
Trial: 28819927
Drug: Immediate-release prednisone
RxNorm normalized name: prednisone Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release prednisone (IR-prednisone)
Trial: 28819932
Drug: Twice-daily (BID)
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily (BID) dosing of 0.075% bromfenac in DuraSite
Trial: 28819932
Drug: Once-daily (QD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily (QD) dosing of 0.075% bromfenac in DuraSite
Trial: 28820321
Drug: Whole-mouth ultrasonic
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Whole-mouth ultrasonic debridement, scaling and root planing, and a 7-day prescription of amoxicillin and metronidazole
Trial: 28822957
Drug: 67 mcg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 67 mcg/kg/day of recombinant human growth hormone (rhGH) for 2 years
Trial: 28823829
Drug: Strict-normal thyroid
RxNorm normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict-normal thyroid function (plasma TSH level 0.4 to 2.5 mIU/L)
Trial: 28823829
Drug: Subclinical hypothyroidism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subclinical hypothyroidism (plasma TSH above 4.5 mIU/L)
Trial: 28823829
Drug: Low-normal thyroid
RxNorm normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-normal thyroid function (plasma TSH level 2.5 to 4.5 mIU/L)
Trial: 28824369
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg daily)
Trial: 28826066
Drug: Acceptance-based interoceptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance-based interoceptive exposure treatment
Trial: 28827212
Drug: Spanish version
RxNorm normalized name: Spanish thyme oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spanish version of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A), delivered as 9 sessions of 55 minutes each by advanced doctoral and masters students in clinical psychology.
Trial: 28829523
Drug: Morphine intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine intravenous patient-controlled analgesia (IV-PCA)
Trial: 28830854
Drug: Conventional preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional preparation methods (infusion rate table)
Trial: 28834619
Drug: High-dose benazepril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose benazepril (mean 69 mg/day, range 40-80)
Trial: 28834619
Drug: High-dose valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose valsartan (mean 526 mg/day, range 320-640)
Trial: 28834619
Drug: High-dose valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose valsartan
Trial: 28834619
Drug: Low-dose benazepril
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose benazepril (20 mg/day)
Trial: 28834619
Drug: Low-dose valsartan
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose valsartan (160 mg/day)
Trial: 28834619
Drug: Extended-release metoprolol
RxNorm normalized name: metoprolol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release metoprolol (mean 152 mg/day, range 23.75-190)
Trial: 28835355
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri DSM 17938 at a dose of 2×10^8 CFU
Trial: 28837404
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine initiation in cancer survivors
Trial: 28837404
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine initiation in general population
Trial: 28837404
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine initiation in adolescent survivors (ages 13 to 17 years)
Trial: 28837404
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine initiation in adolescent peers (ages 13 to 17 years)
Trial: 28837404
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine initiation in young adult survivors (ages 18 to 26 years)
Trial: 28837404
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine initiation in young adult peers (ages 18 to 26 years)
Trial: 28837404
Drug: Predictors of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictors of noninitiation - endorsement of vaccine-related barriers
Trial: 28837405
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg every 2 weeks up to 2 years or until disease progression or unacceptable toxicity
Trial: 28838044
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation with vitamin-K antagonists or non-VKA oral anticoagulants
Trial: 28838044
Drug: Chronic oral
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic oral anticoagulation
Trial: 28838858
Drug: Concurrent cartilage
RxNorm normalized name: SHARK CARTILAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent cartilage thickness change (Y2→Y4)
Trial: 28838886
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving the 12-week physical activity program with weekly group sessions and an individualized, progressive, home-based exercise program.
Trial: 28840147
Drug: Testosterone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (200 mg intramuscularly weekly for 8 weeks)
Trial: 28840147
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline intramuscularly weekly for 8 weeks)
Trial: 31809241
Drug: Osimertinib 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 160 mg once daily
Trial: 28841389
Drug: Osimertinib across
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib across doses
Trial: 28842294
Drug: Preoperative intra-platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative intra-platelet serotonin (IP5-HT) levels >134ng/ml
Trial: 28842294
Drug: Preoperative intra-platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative intra-platelet serotonin (IP5-HT) levels <73ng/ml
Trial: 31471185
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitor treatment
Trial: 28843382
Drug: Air infusion
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air infusion into saline during office hysteroscopy
Trial: 28843918
Drug: Cariprazine 3-12
RxNorm normalized name: cariprazine 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine 3-12 mg/d (mean 6.2 mg/d) for up to 16 weeks
Trial: 28847998
Drug: Venetoclax (50-1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (50-1200 mg, 800 mg in safety expansion) plus bortezomib and dexamethasone
Trial: 28848011
Drug: Ritonavir at
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir at 100 mg daily for 2 weeks, followed by DE 150 mg given 2 h before and simultaneously with ritonavir.
Trial: 28848011
Drug: Cobicistat at
RxNorm normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cobicistat at 150 mg daily for 2 weeks, followed by DE 150 mg given 2 h before and simultaneously with cobicistat.
Trial: 28848667
Drug: Study drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug (specific intervention not mentioned)
Trial: 28848672
Drug: IT-139 (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT-139 (625 mg/m)
Trial: 28848672
Drug: IT-139 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT-139 (various doses: 20, 40, 80, 160, 320, 420, 500, 625, 780 mg/m)
Trial: 28848879
Drug: Twice-Daily Glycopyrrolate
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-Daily Glycopyrrolate
Trial: 28850430
Drug: Locally orientated
RxNorm normalized name: Papaver orientale seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locally orientated treatment for ACNES
Trial: 28851316
Drug: ParvOryx (native
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ParvOryx (native parvovirus H-1) administered intravenously and intratumorally
Trial: 28851415
Drug: Pre-chemotherapy IL-6
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-chemotherapy IL-6 levels
Trial: 28851415
Drug: Pre-chemotherapy D-dimer
RxNorm normalized name: dimer dilinoleyl dimer dilinoleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-chemotherapy D-dimer levels
Trial: 28851423
Drug: PARP inhibitor
RxNorm normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARP inhibitor veliparib in combination with carboplatin (V-C)
Trial: 28851423
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy alone (Control)
Trial: 28851978
Drug: Therapy assessed
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy assessed by changes in SOFA score from admission (T1) to 48 hours later (T2)
Trial: 28854543
Drug: Dexmedetomidine delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine delivered i.v. by target-controlled infusion
Trial: 28854909
Drug: Supplementation with
RxNorm normalized name: Similac For Supplementation with Iron Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation with one tablet of 100 mg feverfew, 100 mg coenzyme Q10 and 112.5 mg magnesium per day for 3 months.
Trial: 28855148
Drug: Immediate ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate ivermectin treatment with antiepilepsy drugs (AEDs)
Trial: 28855148
Drug: Delayed ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed ivermectin treatment (after 4 months) with antiepilepsy drugs (AEDs)
Trial: 28856009
Drug: High water
RxNorm normalized name: Dimethicone 1.5 g in 75 mL TOPICAL CREAM [SONATURAL HIGH WATER DRAW SUPER HYDRA BALM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High water intake (1.0 to 1.5 L/day increase)
Trial: 28857822
Drug: Protease inhibitor-based
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor-based antiretroviral therapy (ART)
Trial: 28857936
Drug: Circumferential anal
RxNorm normalized name: Mephitis mephitis anal gland fluid preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circumferential anal RFA using Barrx 60 RFA focal catheters, median duration of treatment 6.5 minutes (range 5-13 minutes).
Trial: 28859185
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin plus mini-hyper-CVD chemotherapy (1.8 to 1.3 mg/m2 for cycle 1 followed by 1.3 to 1.0 mg/m2 for subsequent cycles).
Trial: 28859185
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin plus mini-hyper-CVD chemotherapy.
Trial: 28859622
Drug: Exposure group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure group (positive for anti-HPA antibody)
Trial: 28859622
Drug: Non-exposure group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-exposure group (negative for anti-HPA antibody)
Trial: 28859648
Drug: Early palliative
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early palliative care (EPC) intervention including in-person outpatient palliative care consultation and telephonic nurse coach sessions with monthly calls.
Trial: 28860229
Drug: Indicators of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indicators of the appropriateness of oral anticoagulant prescriptions developed from hospital information systems.
Trial: 28860229
Drug: Cross-sectional study
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross-sectional study to assess the ability of indicators to detect inappropriate oral anticoagulant prescriptions.
Trial: 28860342
Drug: CUDC-907 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CUDC-907 monotherapy
Trial: 28861121
Drug: Tacrolimus 3
RxNorm normalized name: Tacrolimus 300 microgram/g cutaneous ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus 3 mg daily for 24 weeks
Trial: 28862547
Drug: Preembolization as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preembolization as an adjunct to surgery or radiotherapy (second RCT)
Trial: 28862877
Drug: Mepolizumab (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (750 mg intravenous dose)
Trial: 28864814
Drug: Rituximab 375
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2 added to corticosteroids (CSs) and cyclosporine A (CsA) as first-line therapy for cGVHD.
Trial: 28866290
Drug: PHiD-CV (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHiD-CV (2 doses for unprimed, 1 dose for primed)
Trial: 28866726
Drug: 6 week
RxNorm normalized name: tobramycin 28 MG inhalation powder 56 Weekly Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 week course of antibiotics
Trial: 28866726
Drug: 12 week
RxNorm normalized name: risedronate sodium 35 MG Oral Tablet, 12 Week Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 week course of antibiotics
Trial: 28866779
Drug: Live oral
RxNorm normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live oral poliovirus vaccine (OPV)
Trial: 28867665
Drug: Oral baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral baclofen (dosage not specified)
Trial: 28869617
Drug: Yttrium-90 ibritumomab
RxNorm normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yttrium-90 ibritumomab tiuxetan, dosage not specified, duration not specified
Trial: 28870611
Drug: TargomiRs (miR-16-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TargomiRs (miR-16-based mimic microRNA) administered via 20 min intravenous infusion either once or twice a week in a traditional 3+3 dose-escalation design in five dose cohorts.
Trial: 28873076
Drug: Propofol sedation
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol sedation using electroencephalogram monitoring during a constant level of sedation depth (D0 to D2) performed by trained nurses or physicians after a body-weight-adjusted loading dose.
Trial: 28874545
Drug: Immune complexes
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune complexes composed of sialylated antihemagglutinin antibodies and seasonal inactivated flu vaccine (TIV)
Trial: 28874545
Drug: Fc-modified, bispecific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fc-modified, bispecific monoclonal antibody against conserved epitopes of the hemagglutinin combined with TIV
Trial: 28874669
Drug: Treatment response
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment response in patient-derived models
Trial: 28877684
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation intervention (not specified in detail, but includes nicotine replacement therapy or other cessation aids offered to 42% of smokers)
Trial: 28877863
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% imiquimod cream, applied three times a week for 16 weeks
Trial: 28878005
Drug: Citrate Anticoagulant
RxNorm normalized name: ANTICOAGULANT CITRATE DEXTROSE
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citrate Anticoagulant
Trial: 28879038
Drug: Functional and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional and individualised neuromuscular exercise therapy (ET), 12 weeks, 3 sessions per week supervised by trained physical therapists.
Trial: 28879040
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of calcium channel blocker (CCB) with angiotensin receptor blocker (ARB)
Trial: 28879040
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of thiazide diuretic with angiotensin receptor blocker (ARB)
Trial: 28879040
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of calcium channel blocker (CCB) with ARB
Trial: 28879040
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of thiazide diuretic with ARB
Trial: 28880374
Drug: Hydroxycarbamide (HC)
RxNorm normalized name: hydroxycarbamide
DrugBank: Hydroxyurea (DB01005)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydroxycarbamide (HC) treatment
Trial: 28881319
Drug: 25mg intravenous
RxNorm normalized name: estrogens, conjugated (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg intravenous (IV) cocaine
Trial: 28881389
Drug: Subcutaneous immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunoglobulin (SCIg)